The FREND COVID-19 Neutralization Ab can be used to check whether a patient has developed the immune response to SARS-CoV-2 using human serum or plasma (EDTA). The FREND COVID-19 Neutralization Ab is a fluorescence immunoassay (FIA) using the FREND System intended for the qualitative detection of neutralization antibodies to SARS-CoV-2. 

The FREND COVID-19 Neutralization Ab is intended for use as an aid in identifying individuals with neutralizing antibodies to

 SARS-CoV-2 after vaccination or prior infection.

Using small amount of sample, the FREND System provides accurate results.

Performance evaluation

Clinical Performance Evaluation

A total of 41 clinical samples (28 positive and 13 negative) confirmed with PRNT50 were tested with

the FREND COVID-19 Neutralization Ab, demonstrating 92.9% PPA* and 100% NPA* as shown below.

Effective Data Management

Laboratory Information System Connectivity

In the event of a pandemic, the management of a vast amount of clinical results is important. As many laboratories face challenges in effective arrangement of the essential information, the FREND System provides the following advantages: